English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAn international team of neuro-oncology researchers and clinicians has released new recommendations for good clinical practice regarding the use of artificial intelligence methods to more accurately diagnose, monitor and treat brain cancer.
Tag: Brain Tumor Research
In 10 seconds, an AI model detects cancerous brain tumor often missed during surgery
Researchers have developed an AI powered model that — in 10 seconds — can determine during surgery if any part of a cancerous brain tumor that could be removed remains, a study published in Nature suggests. The technology, called FastGlioma, outperformed conventional methods for identifying what remains of a tumor by a wide margin. Researchers say it has the potential to change the field of neurosurgery by immediately improving comprehensive management of patients with diffuse gliomas.
White House Names Abramson Cancer Center Neuro-Oncologist a Cancer Moonshot Scholar
The Biden Cancer Moonshot Program named Penn Medicine’s Richard E. Phillips, MD, PhD, Chief of the Division of Neuro-Oncology and an assistant professor of Neurology, a Cancer Moonshot Scholar today. Phillips is among 11 scholars included in this year’s cohort, who together will receive a total of $6 million to support cancer research and innovation across the country. The $2.4 million grant will support Phillips as he researches tumor epigenetics, an emerging field pertaining to how changes to DNA can impact the development of cancer cells, with a specific focus on brain tumors in children and young adults.
Breakthrough UC San Diego Brain Recording Device Receives FDA Approval for a Clinical Trial
The Federal Drug Administration approved a clinical trial to test the effectiveness of an electronic grid that records brain activity during surgery, developed by engineers at the University of California San Diego.
Safety concerns raised for neuroblastoma candidate drug
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.